Associations of inflammatory and hemostatic variables with the risk of recurrent stroke

Stroke

Volumn 36, Issue 10, 2005, Pages 2143-2147

  Woodward, Mark ^a   Lowe, Gordon D O ^b,f   Campbell, Duncan J ^c,d   Colman, Sam ^a   Rumley, Ann ^b   Chalmers, John ^a   Neal, Bruce C ^a   Patel, Anushka ^a   Jenkins, Alicia J ^d   Kemp, Bruce E ^c,d,e   MacMahon, Stephen W ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ST VINCENT S HOSPITAL   (Australia)

^d ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e CSIRO   (Australia)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Hemostasis; Inflammation; Stroke

Indexed keywords

ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; D DIMER; FIBRIN; FIBRINOGEN; INDAPAMIDE; PERINDOPRIL; PLACEBO; STATINE DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PLASMA VISCOSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SMOKING; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK;

EID: 26444439079     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000181754.38408.4c     Document Type: Article

References (38)

1. Lowe GDO, Rumley A, Whincup PH, Danesh J. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med. 2002;2:429-440.
2. Lowe GDO. Fibrinogen: an independent coronary heart disease risk factor. In: Betteridge DJ, ed. Lipids and Vascular Disease. London, UK: Dunitz; 2000:77-84.
3. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. J Am Med Assoc. 1998;279:1477-1482.
4. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol. 1999;19:1368-1377.
5. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
6. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. J Am Med Assoc. 1987;258:1183-1186.
7. Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1997;17:3321-3325.
8. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FGR, Lowe GDO. Hemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol. 1998;100:758-763.
9. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol. 1999;19:1776-1783.
10. Baker IA, Pickering J, Elwood PC, Bayer A, Ebrahim S. Fibrinogen, viscosity and white blood cell count predict myocardial, but not cerebral infarction: evidence from the Caerphilly and Speedwell cohort. Thromb Haemost. 2002;87:421-425.
11. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 1991;83:836-844.
12. Sweetnam PM, Thomas HF, Yarnell JWG, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. The Caerphilly and Speedwell Studies. Eur Heart J. 1996;17:1814-1820.
13. Lowe GDO, Lee AJ, Rumley A, Price JF, Fowkes FGR. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997;96:168-173.
14. Lowe GDO, Rumley A, Nome J, Ford I, Shepherd J, Cobbe S, Macfarlane P, Packard C; West of Scotland Coronary Prevention Group. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost. 2000;84:553-558.
15. Danesh J, Collins R, Peto R, Lowe GDO. Haematocrit, viscosity, erthryocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J. 2000;21:515-520.
16. Lee AJ, Mowbray PI, Lowe GDO, Rumley A, Fowkes FGR, Allan PL. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation. 1998;97:1467-1473.
17. Ernst E, Resch KL, Matrai A, Buhl M, Schlosser P, Paulsen HF. Impaired blood rheology: a risk factor after stroke? J Intern Med. 1991;229:457-462.
18. Martin JF, Bath PMW, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991;338:1409-1411.
19. Danesh J, Wheeler JG, Hirshfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
20. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GDO. Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002;23:1764-1770.
21. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GDO. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001;103:2323-2327.
22. Lowe GDO, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH. Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2004;25:252-259.
23. Gussekloo J, Schaap MCL, Frolich M, Blauw GJ, Westendorp RGJ. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000;20:1047-1051.
24. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: Findings from the Third National Health and Examination Survey. Arterioscler Thromb Vasc Biol. 2000;20:1052-1056.
25. Folsom AR, Wu KK, Rosamond WD, Sharett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:1102-1108.
26. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
27. Nilsson TK, Jansson JH, Bowman K. tPA-PAI-1 complex as a risk factor for the development of a first stroke. Fibrinolysis 1998;12(suppl 1):21 (abstract).
28. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens. 1996;14(suppl 2):s41-s46.
29. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
30. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994;24:444-453.
31. Woodward M, Lowe GDO, Rumley A, Imhof A, Koenig W. Measurement of plasma viscosity in stored frozen samples: a general population study. Blood Coagul Fibrinolysis. 2003;14:417-420.
32. Woodward M. Epidemiology: Study Design and Data Analysis. Second edition. Boca Raton, Fla: Chapman and Hall/CRC Press; 2005.
33. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MFG, Warlow CP; Cerebrovascular Cohort Studies Collaboration. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004;35:2300-2305.
34. Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective observational studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil. 2004;11:9-17.
35. Lowe GDO. The pharmacology of thrombolytic and ftbrinogen-depleting agents in the treatment of acute ischaemic stroke. Cerebrovasc Dis. 1998;8(suppl 1):36-42.
36. Lowe GDO. Ancrod in treatment of acute ischaemic stroke. Proc R Coll Physicians Edinb. 2001;31(suppl 8):20-24.
37. Tait RC, Murdoch DL, O'Neill KF, McMahon A, Wallace IW, Rumley A, Jackson J, Lowe GDO. Fibrin D-dimer is an independent predictor of future stroke in patients with atrial fibrillation. Circulation. 2003;108:787.
38. Vene N, Mavri A, Koxmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemostasis. 2003;90:1163-1172.